Ralph Tiedt
Jnana Therapeutics (United States)(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Myeloproliferative Neoplasms: Diagnosis and Treatment, Fibroblast Growth Factor Research, Protein Degradation and Inhibitors, Lung Cancer Treatments and Mutations
Most-Cited Works
- → A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders(2005)3,434 cited
- → Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening(2017)693 cited
- → Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma(2016)532 cited
- → Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice(2007)432 cited
- → Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo(2006)414 cited
- → Talin is required for integrin-mediated platelet function in hemostasis and thrombosis(2007)302 cited
- → Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion(2007)179 cited
- → Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2(2005)177 cited
- → Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation(2019)173 cited
- → Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition(2012)162 cited